The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Selecting patients with secondary AML for CPX-351
In this video, Fabio Guolo, MD, University of Genoa, Genoa, Italy, briefly comments on the selection of patients with secondary acute myeloid leukemia (AML) for treatment with CPX-351, highlighting that the treatment confers improved tolerability compared to conventional chemotherapy. Dr Guolo suggests CPX-351 is best combined with allogeneic stem cell transplantation in patients who are fit and transplant-eligible. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think that the most important information is to choose the right patient for the CPX. A patient who is a candidate for CPX should be a fit patient. Probably the combination of CPX-351 and allogeneic stem cell transplantation provides the better results. So patients who are eligible for transplant and have secondary AML, I think they should receive CPX-351. It’s important to know that CPX-351 is an intensive treatment but is better tolerated than conventional chemotherapy...
I think that the most important information is to choose the right patient for the CPX. A patient who is a candidate for CPX should be a fit patient. Probably the combination of CPX-351 and allogeneic stem cell transplantation provides the better results. So patients who are eligible for transplant and have secondary AML, I think they should receive CPX-351. It’s important to know that CPX-351 is an intensive treatment but is better tolerated than conventional chemotherapy. So, some patients who are not probably considered fit for conventional 3 plus 7 may still be eligible for CPX-351. There are some results from the Italian group who are studying this aspect and they showed that CPX-351 is less toxic on the gut and other extramedullary organs. So that may explain why it’s better tolerated.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
